ArticleInvestigative ophthalmology & visual science2026
Xanthophyll Carotenoid Intake, Plasma Levels, and Retinal Visualization in Aging and Age-Related Macular Degeneration: ALSTAR2.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Purpose: The purpose of this study was to determine cross-sectional associations among intake of xanthophyll carotenoids lutein and zeaxanthin (L&Z), plasma L&Z, and two wavelength autofluorescence (2WAF) retinal imaging in aging and age-related macular degeneration (AMD). Methods: Adults ≥63 years old from a comprehensive ophthalmology clinic underwent assessments: macular health (Age-Related Eye Disease Study [AREDS] 9-step); self-reported L&Z intake from diet (LZQ Food Frequency Questionnaire) and supplements; total intake; macular pigment optical volume (MPOV; in 2WAF); non-fasting plasma L&Z; and HDL and LDL cholesterol. Associations were adjusted for age and HDL/LDL. Results: We studied 369 persons (74 ± 5.8 years, 60% women, 89% White, 62% never-smoker, and 23% supplement use) and 369 eyes (48.4% healthy, 26.0% early AMD [eAMD], and 25.2% intermediate AMD [iAMD]). Diagnostic groups differed in supplement users (10%, 17%, and 56%), total L&Z intake (5.3 ± 6.4, 5.5 ± 5.4, and 11.0 ± 8.3 mg/d, P < 0.01), and MPOV (1.04 ± 0.46, 1.02 ± 0.52, and 1.33 ± 0.61). Groups did not differ in dietary intake (3.8 ± 4.5, 3.4 ± 3.2, and 3.7 ± 3.8 mg/d), plasma HDL, or HDL/LDL. Associations were strong between plasma L&Z and MPOV (r = 0.41-0.67, P < 0.01); moderate between total intake and plasma L&Z (Spearman r = 0.29-0.50, P < 0.01); weaker but significant for L&Z intake, and MPOV (r = 0.22-0.30, P < 0.01) of 3-mm-diameter macula lutea only, for eAMD and iAMD. Conclusions: In a large US sample, we assess for the first time L&Z intake from diet and supplements and determined the relative strength of correlations among intake, plasma, and retinal xanthophylls. We replicate our earlier finding of elevated retinal and plasma L&Z in iAMD. LZQ and 2WAF are suitable outcome measures for future interventions that directly test the impact of L&Z on AMD onset and progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.